Evidence map›Paper›PMID 42264885›Full record

ArticleBMJ open respiratory research2026

Toll interacting protein (TOLLIP) serum concentration in patients with systemic sclerosis (SSc), with and without interstitial lung disease (ILD).

Niels Schröder, Jitka Andrä, Diana Knuth-Rehr, Silke Leja, Nicolas Hunzelmann, Eda Börner, Kimberly Barbet, Francesco Bonella

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Niels SchröderCenter for Interstitial and Rare Lung Diseases, Ruhrlandklinik, Pneumonology Department, University of Duisburg-Essen, Essen, NRW, Germany.ORCID http://orcid.org/0009-0001-4956-5657
Jitka AndräCenter for Interstitial and Rare Lung Diseases, Ruhrlandklinik, Pneumonology Department, University of Duisburg-Essen, Essen, NRW, Germany.
Diana Knuth-RehrDepartment of Dermatology and Venereology, University Hospital Cologne, Cologne, NRW, Germany.
Silke LejaDepartment of Dermatology and Venereology, University Hospital Cologne, Cologne, NRW, Germany.
Nicolas HunzelmannDepartment of Dermatology and Venereology, University Hospital Cologne, Cologne, NRW, Germany.
Eda BörnerCenter for Interstitial and Rare Lung Diseases, Ruhrlandklinik, Pneumonology Department, University of Duisburg-Essen, Essen, NRW, Germany.
Kimberly BarbetCenter for Interstitial and Rare Lung Diseases, Ruhrlandklinik, Pneumonology Department, University of Duisburg-Essen, Essen, NRW, Germany.
Francesco BonellaCenter for Interstitial and Rare Lung Diseases, Ruhrlandklinik, Pneumonology Department, University of Duisburg-Essen, Essen, NRW, Germany Francesco.Bonella@rlk.uk-essen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSingle nucleotide polymorphisms (SNPs) within Toll interacting protein ( PATIENTS AND

methods106 consecutive patients with SSc (77 female) with (n=53) and without ILD (n=53) and 60 healthy controls (HCs) were included. TOLLIP concentrations were measured using a commercially available ELISA kit (Cloud-Clone, USA) in serum samples from patients and HC previously genotyped for two SNPs within

resultsPatients with SSc had tendentially lower TOLLIP serum concentrations than HC (0.111 (95% CI 0.101 to 0.123) vs 0.141 (95% CI 0.104 to 0.191) ng/µL, p=0.076). Patients with SSc-ILD showed significantly higher TOLLIP levels than patients with SSc without ILD (0.126 (95% CI 0.106 to 0.151) vs 0.098 (95% CI 0.091 to 0.105) ng/µL, p=0.010). At a cut-off value of ≥0.1135 ng/µL serum TOLLIP yielded a 71% sensitivity and 74% specificity for identifying ILD (AUC=0.74, 95% CI 0.593 to 0.889, p=0.007). Serum TOLLIP concentrations did not differ significantly across rs3750920 or rs5743890 genotypes. TOLLIP concentration inversely correlated with age (r=-0.256, p<0.001), whereas no significant associations with gender, body mass index, C-reactive protein, forced vital capacity or diffusing capacity of the lung for carbon monoxide at time of sampling were observed.

conclusionPatients with SSc show lower TOLLIP serum concentrations than HC, while patients with SSc-ILD exhibit higher TOLLIP levels than those without. TOLLIP might serve as a biomarker of ILD in patients with SSc.

Indexed as

Intracellular Signaling Peptides and ProteinsLung Diseases, InterstitialScleroderma, SystemicAdultAgedBiomarkersCase-Control StudiesFemaleGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotideBiomarkersIntracellular Signaling Peptides and ProteinsTOLLIP protein, humanInnate ImmunityInterstitial FibrosisPatient Outcome AssessmentRare lung diseases

Identifiers

PMID42264885
PMCPMC13264915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.